Anglo-Swedish drugs giant AstraZeneca PLC (LON:AZN) has been granted a priority review from the US Food and Drug Administration for its supplemental new drug application for its Lynparza breast cancer drug.
The FTSE 100 group said it expects to back from the regulator in the first quarter of 2018.
READ: AstraZeneca’s Imfinzi cancer drug clears another regulatory hurdle
Astra’s application is based on positive results from the phase III OlympiAD trial, which tested 300mg Lynparza tablets (taken twice a day) on 302 patients with HER2-negative metastatic breast cancer.
Lynparza was first approved by the FDA back in December 2014 and has since been used to treat advanced ovarian cancer patients, but AstraZeneca reckons it could be useful in the treatment of other cancer types, including breast, prostate and pancreatic.
Shares were 0.5% higher at £51.91 on Wednesday afternoon.
--Updates for share price--